-
2
-
-
42449085034
-
Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients
-
Horberg M, Silverberg M, Hurley L, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384-90.
-
(2008)
J Acquir Immune Defic Syndr
, vol.47
, pp. 384-390
-
-
Horberg, M.1
Silverberg, M.2
Hurley, L.3
-
3
-
-
15044359069
-
Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients
-
Yun L, Maravi M, Kobayashi J, Barton P, Davidson A. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432-8.
-
(2005)
J Acquir Immune Defic Syndr
, vol.38
, pp. 432-438
-
-
Yun, L.1
Maravi, M.2
Kobayashi, J.3
Barton, P.4
Davidson, A.5
-
4
-
-
33846027983
-
Practice Guidelines for the Treatment of Psychiatric Disorders
-
American Psychiatric Association. American Psychiatric Association
-
American Psychiatric Association. Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2006. American Psychiatric Association 2006.
-
(2006)
Compendium 2006
-
-
-
5
-
-
0037362750
-
Use of Psychotropic Medications among HIV-Infected Patients in the United States
-
Vitiello B, Burnam M, Bing E, Beckman R, Shapiro M. Use of Psychotropic Medications Among HIV-Infected Patients in the United States. Am J Psychiatry. 2003;160:547-54.
-
(2003)
Am J Psychiatry
, vol.160
, pp. 547-554
-
-
Vitiello, B.1
Burnam, M.2
Bing, E.3
Beckman, R.4
Shapiro, M.5
-
6
-
-
0037223881
-
Drug interactions between antiretroviral drugs and comedicated agents
-
de Maat M, Ekhart G, Huitema A, Koks C, Mulder J, Beijnen J. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet. 2003;42:223-82.
-
(2003)
Clin Pharmacokinet
, vol.42
, pp. 223-282
-
-
De Maat, M.1
Ekhart, G.2
Huitema, A.3
Koks, C.4
Mulder, J.5
Beijnen, J.6
-
7
-
-
0032940948
-
Significant interactions with new antiretrovirals and psychotropic drugs
-
Tseng A, Foisy M. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother. 1999;33:461-73.
-
(1999)
Ann Pharmacother
, vol.33
, pp. 461-473
-
-
Tseng, A.1
Foisy, M.2
-
8
-
-
0037049347
-
Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipoICoNa Study
-
Galli M, Cozzi-Lepri A, Ridolfo A, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002;162:2621-8.
-
(2002)
Arch Intern Med
, vol.162
, pp. 2621-2628
-
-
Galli, M.1
Cozzi-Lepri, A.2
Ridolfo, A.3
-
9
-
-
0034631873
-
Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
-
Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-6.
-
(2000)
Arch Intern Med
, vol.160
, pp. 2050-2056
-
-
Tsiodras, S.1
Mantzoros, C.2
Hammer, S.3
-
10
-
-
0012570692
-
Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
-
Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14:37-49.
-
(2000)
AIDS
, vol.14
, pp. 37-49
-
-
Saint-Marc, T.1
Partisani, M.2
Poizot-Martin, I.3
-
12
-
-
0033730425
-
Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors
-
Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14:F123-8.
-
(2000)
AIDS
, vol.14
-
-
Maggi, P.1
Serio, G.2
Epifani, G.3
-
13
-
-
17144463863
-
Severe premature coronary artery disease with protease inhibitors
-
Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
-
(1998)
Lancet
, vol.351
, pp. 1328
-
-
Henry, K.1
Melroe, H.2
Huebsch, J.3
-
14
-
-
0033527333
-
Myocardial infarction in HIV-infected men receiving protease inhibitors
-
Flynn T, Bricker L. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med. 1999;131:548.
-
(1999)
Ann Intern Med
, vol.131
, pp. 548
-
-
Flynn, T.1
Bricker, L.2
-
15
-
-
17444405568
-
Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: A cross-sectional study
-
Mackin P, Watkinson H, Young A. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005;48:215-21.
-
(2005)
Diabetologia
, vol.48
, pp. 215-221
-
-
Mackin, P.1
Watkinson, H.2
Young, A.3
-
16
-
-
13244294222
-
A review of metabolic issues in atypical antipsychotic treatment
-
Newcomer J, Nasrallah H. A review of metabolic issues in atypical antipsychotic treatment. Adv Studies Med. 2004;4:S1045-58.
-
(2004)
Adv Studies Med
, vol.4
-
-
Newcomer, J.1
Nasrallah, H.2
-
17
-
-
27744581955
-
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
-
Goff D, Sullivan L, McEvoy J, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53.
-
(2005)
Schizophr Res
, vol.80
, pp. 45-53
-
-
Goff, D.1
Sullivan, L.2
McEvoy, J.3
-
18
-
-
0028268944
-
Use of psychotropic drugs in patients with HIV infection
-
Ayuso J. Use of psychotropic drugs in patients with HIV infection. Drugs. 1994;47:599-610.
-
(1994)
Drugs
, vol.47
, pp. 599-610
-
-
Ayuso, J.1
-
19
-
-
0033746611
-
Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia
-
Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol. 2000;14:222-7.
-
(2000)
J Psychopharmacol
, vol.14
, pp. 222-227
-
-
Nath, A.1
Anderson, C.2
Jones, M.3
-
21
-
-
0034455640
-
Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection
-
Gerber J. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis. 2000;30:S123-9.
-
(2000)
Clin Infect Dis
, vol.30
-
-
Gerber, J.1
-
22
-
-
0030756282
-
Drug interaction potential with inhibitors of HIV protease
-
Van Cleef G, Fisher E, Polk R. Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy. 1997;17:774-8.
-
(1997)
Pharmacotherapy
, vol.17
, pp. 774-778
-
-
Van Cleef, G.1
Fisher, E.2
Polk, R.3
-
23
-
-
0032556976
-
Drug interactions in HIV-positive patients initiated on protease inhibitor therapy
-
Preston S, Postelnick M, Purdy B, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS. 1998;12:228-30.
-
(1998)
AIDS
, vol.12
, pp. 228-230
-
-
Preston, S.1
Postelnick, M.2
Purdy, B.3
-
24
-
-
84862517441
-
-
Denver University of Colorado at Denver and Health Sciences Center. Available at
-
Wolbach-Lowes J, Jed S, Johnson S, Fletcher C, Brown B. A Pharmacist's Guide to Antiretroviral Medications for HIV-Infected Adults and Adolescents. Denver, Mountain Plains AIDS Education and Training Center, University of Colorado at Denver and Health Sciences Center. Available at: http://www.aidsetc.org/pdf/p02-et/et-03-00/pharm2005.pdf
-
A Pharmacist's Guide to Antiretroviral Medications for HIV-Infected Adults and Adolescents
-
-
Wolbach-Lowes, J.1
Jed, S.2
Johnson, S.3
Fletcher, C.4
Brown, B.5
-
25
-
-
50949103536
-
Psychopharmacology in HIV-infected patients
-
Repetto M, Petitto J. Psychopharmacology in HIV-infected patients. Psychosom Med. 2008;70:585-92.
-
(2008)
Psychosom Med
, vol.70
, pp. 585-592
-
-
Repetto, M.1
Petitto, J.2
-
26
-
-
0024440344
-
Anxiety and neuropsychiatry of AIDS
-
Fernandez F. Anxiety and neuropsychiatry of AIDS. J Clin Psychiatry. 1989;50:9-14.
-
(1989)
J Clin Psychiatry
, vol.50
, pp. 9-14
-
-
Fernandez, F.1
-
27
-
-
18744399306
-
Antiretrovirals. Part III: Antiretrovirals and drugs of abuse
-
Wynn G, Cozza K, Zapor M, Wortmann G, Armstrong S. Antiretrovirals. Part III: antiretrovirals and drugs of abuse. Psychosomatics. 2005;46:79-87.
-
(2005)
Psychosomatics
, vol.46
, pp. 79-87
-
-
Wynn, G.1
Cozza, K.2
Zapor, M.3
Wortmann, G.4
Armstrong, S.5
-
28
-
-
0034056369
-
Alprazolam-ritonavir interactions: Implications for product labelling
-
Greenblatt D, von Moltke L, Harmatz J, et al. Alprazolam-ritonavir interactions: implications for product labelling. Clin Pharmacol Ther. 2000;67:335-47.
-
(2000)
Clin Pharmacol Ther
, vol.67
, pp. 335-347
-
-
Greenblatt, D.1
Von Moltke, L.2
Harmatz, J.3
-
29
-
-
0034209862
-
Differential impairment of triazolam and zolpidem clearance by ritonavir
-
Greenblatt D, von Moltke L, Harmatz J, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr. 2000;24:129-36.
-
(2000)
J Acquir Immune Defic Syndr
, vol.24
, pp. 129-136
-
-
Greenblatt, D.1
Von Moltke, L.2
Harmatz, J.3
-
31
-
-
0027530429
-
Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient
-
Mole L, Israelski D, Bubp J, O'Hanley P, Merigan T, Blaschke T. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr. 1993;6:56-60.
-
(1993)
J Acquir Immune Defic Syndr
, vol.6
, pp. 56-60
-
-
Mole, L.1
Israelski, D.2
Bubp, J.3
O'Hanley, P.4
Merigan, T.5
Blaschke, T.6
-
32
-
-
78649655790
-
Psychiatric treatment of persons with HIV/AIDS: An HIV-psychiatry consensus survey of current practices
-
Freudenreich O, Goforth H, Cozza K, et al. Psychiatric treatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices. Psychosomatics. 2010;51:480-8
-
(2010)
Psychosomatics
, vol.51
, pp. 480-488
-
-
Freudenreich, O.1
Goforth, H.2
Cozza, K.3
-
33
-
-
67650472819
-
The pharmacologic management of insomnia in patients with HIV
-
Omonuwa T, Goforth H, Preud'homme X, et al. The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med. 2009;5:251-62.
-
(2009)
J Clin Sleep Med
, vol.5
, pp. 251-262
-
-
Omonuwa, T.1
Goforth, H.2
Preud'homme, X.3
-
34
-
-
0025293443
-
Buspirone in drug users with AIDS or AIDS-related complex
-
Batki S. Buspirone in drug users with AIDS or AIDS-related complex. J Clin Psychopharmacol. 1990;10:111-15S.
-
(1990)
J Clin Psychopharmacol
, vol.10
-
-
Batki, S.1
-
35
-
-
32944482387
-
An overview of psychotropic drugdrug interactions
-
Sandson N, Armstrong S, Cozza K. An overview of psychotropic drugdrug interactions. Psychosomatics. 2005;46:464-94.
-
(2005)
Psychosomatics
, vol.46
, pp. 464-494
-
-
Sandson, N.1
Armstrong, S.2
Cozza, K.3
-
36
-
-
77955714260
-
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
-
Altice F, Kamarulzaman A, Soriano V, Schechter M, Friedland G. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367-87.
-
(2010)
Lancet
, vol.376
, pp. 367-387
-
-
Altice, F.1
Kamarulzaman, A.2
Soriano, V.3
Schechter, M.4
Friedland, G.5
-
37
-
-
0035885023
-
Management of psychiatric disorders in patients infected with human immunodeficiency virus
-
Angelino A, Treisman G. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:847-56.
-
(2001)
Clin Infect Dis
, vol.33
, pp. 847-856
-
-
Angelino, A.1
Treisman, G.2
-
38
-
-
0036511084
-
Psychopharmacological treatment of patients with HIV and AIDS
-
Ferrando S, Wapanyi K. Psychopharmacological treatment of patients with HIV and AIDS. Psychiatr Q. 2002;73:33-49.
-
(2002)
Psychiatr Q
, vol.73
, pp. 33-49
-
-
Ferrando, S.1
Wapanyi, K.2
-
39
-
-
0028354623
-
Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness
-
Rabkin J, Rabkin R, Harrison W, Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry. 1994;151:516-23.
-
(1994)
Am J Psychiatry
, vol.151
, pp. 516-523
-
-
Rabkin, J.1
Rabkin, R.2
Harrison, W.3
Wagner, G.4
-
40
-
-
0034177434
-
Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
-
Anderson I. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
-
(2000)
J Affect Disord
, vol.58
, pp. 19-36
-
-
Anderson, I.1
-
42
-
-
0030889634
-
Efficacy of paroxetine for treatment of depression in the context of HIV infection
-
Grassi B, Gambini O, Graghentini A, et al. Efficacy of paroxetine for treatment of depression in the context of HIV infection. Pharmacotherapy. 1997;30:70-1.
-
(1997)
Pharmacotherapy
, vol.30
, pp. 70-71
-
-
Grassi, B.1
Gambini, O.2
Graghentini, A.3
-
43
-
-
0031924994
-
Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants
-
Baker G, Fang J, Sinha S, Coutts R. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev. 1998;22:325-33.
-
(1998)
Neurosci Biobehav Rev
, vol.22
, pp. 325-333
-
-
Baker, G.1
Fang, J.2
Sinha, S.3
Coutts, R.4
-
44
-
-
0036219021
-
Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update
-
Hemeryck A, Belpaire F. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13-37.
-
(2002)
Curr Drug Metab
, vol.3
, pp. 13-37
-
-
Hemeryck, A.1
Belpaire, F.2
-
45
-
-
11144238371
-
Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV
-
Caballero J, Nahata M. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother. 2005;39:141-5.
-
(2005)
Ann Pharmacother
, vol.39
, pp. 141-145
-
-
Caballero, J.1
Nahata, M.2
-
46
-
-
2442529601
-
Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: A prospective study
-
Currier M, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics. 2004;45:210-16.
-
(2004)
Psychosomatics
, vol.45
, pp. 210-216
-
-
Currier, M.1
Molina, G.2
Kato, M.3
-
47
-
-
28344442596
-
Duloxetine: A balanced and selective norepinephrine and serotonin-reuptake inhibitor
-
Westanmo A, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine and serotonin-reuptake inhibitor. Am J Health Syst Pharm. 2005;62:2481-90.
-
(2005)
Am J Health Syst Pharm
, vol.62
, pp. 2481-2490
-
-
Westanmo, A.1
Gayken, J.2
Haight, R.3
-
48
-
-
79951996267
-
Desvenlafaxine in major depressive disorder: An evidence-based review of its place in therapy
-
Lieberman D, Massey S. Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2009;4:67-82.
-
(2009)
Core Evid
, vol.4
, pp. 67-82
-
-
Lieberman, D.1
Massey, S.2
-
49
-
-
0038710739
-
An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder
-
Carvalhal A, de Abreu P, Spode A, Correa J, Kapczinski F. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. J Clin Psychiatry. 2003;64:421-4.
-
(2003)
J Clin Psychiatry
, vol.64
, pp. 421-424
-
-
Carvalhal, A.1
De Abreu, P.2
Spode, A.3
Correa, J.4
Kapczinski, F.5
-
50
-
-
0037369155
-
A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients
-
Currier M, Molina G, Kato M. A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics. 2003;44:120-5.
-
(2003)
Psychosomatics
, vol.44
, pp. 120-125
-
-
Currier, M.1
Molina, G.2
Kato, M.3
-
51
-
-
0035150854
-
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion
-
Hesse L, von Moltke L, Shader R, Greenblatt D. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001;29:100-2.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 100-102
-
-
Hesse, L.1
Von Moltke, L.2
Shader, R.3
Greenblatt, D.4
-
52
-
-
0032908843
-
Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: An open trial of nefazodone
-
Elliott A, Russo J, Bergam K, Claypoole K, Uldall K, Roy-Byrne P. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. J Clin Psychiatry. 1999;60:226-31.
-
(1999)
J Clin Psychiatry
, vol.60
, pp. 226-231
-
-
Elliott, A.1
Russo, J.2
Bergam, K.3
Claypoole, K.4
Uldall, K.5
Roy-Byrne, P.6
-
53
-
-
0037382219
-
Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone
-
Greenblatt D, von Moltke L, Harmatz J, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003;43:414-22.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 414-422
-
-
Greenblatt, D.1
Von Moltke, L.2
Harmatz, J.3
-
54
-
-
0034128559
-
Mirtazapine for depression in patients with human immunodeficiency virus
-
Elliott A, Roy-Byrne P. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol. 2000;20:265-7.
-
(2000)
J Clin Psychopharmacol
, vol.20
, pp. 265-267
-
-
Elliott, A.1
Roy-Byrne, P.2
-
55
-
-
80051796810
-
Novel melatonin-based therapies: Potential advances in the treatment of major depression
-
Hickie I, Rogers N. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378:621-31.
-
(2011)
Lancet
, vol.378
, pp. 621-631
-
-
Hickie, I.1
Rogers, N.2
-
56
-
-
76149131974
-
Agomelatine: A novel pharmacological approach to treating depression
-
Barc
-
Owen R. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc). 2009;45:599-608.
-
(2009)
Drugs Today
, vol.45
, pp. 599-608
-
-
Owen, R.1
-
57
-
-
0029047853
-
Effects of methylphenidate in HIV-related depression: A comparative trial with deispramine
-
Fernandez F, Levy J, Samley H, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with deispramine. Int J Psychiatry Med. 1995;25:53-67.
-
(1995)
Int J Psychiatry Med
, vol.25
, pp. 53-67
-
-
Fernandez, F.1
Levy, J.2
Samley, H.3
-
58
-
-
0033947427
-
Effects of dextroamphetamine on depression and fatigue in men with HIV: A double-blind placebo controlled trial
-
Wagner G, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind placebo controlled trial. J Clin Psychiatry. 2000;61:436-40.
-
(2000)
J Clin Psychiatry
, vol.61
, pp. 436-440
-
-
Wagner, G.1
Rabkin, R.2
-
59
-
-
0035847581
-
A randomized, double- Blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus
-
Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double- blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus. Arch Intern Med. 2001;161:411-20.
-
(2001)
Arch Intern Med
, vol.161
, pp. 411-420
-
-
Breitbart, W.1
Rosenfeld, B.2
Kaim, M.3
Funesti-Esch, J.4
-
60
-
-
0024237865
-
Effect of lithium carbonate in HIV-infected patients with immune dysfunction
-
Parenti D, Simon G, Scheib R, et al. Effect of lithium carbonate in HIV-infected patients with immune dysfunction. J Acquir Immune Defic Syndr. 1988;1:119-24.
-
(1988)
J Acquir Immune Defic Syndr
, vol.1
, pp. 119-124
-
-
Parenti, D.1
Simon, G.2
Scheib, R.3
-
61
-
-
33748488655
-
Lithium improves HIV-associated neurocognitive impairment
-
HNRC Group
-
Letendre S, Woods S, Ellis R, et al. HNRC Group. Lithium improves HIV-associated neurocognitive impairment. AIDS. 2006;20:1885-8.
-
(2006)
AIDS
, vol.20
, pp. 1885-1888
-
-
Letendre, S.1
Woods, S.2
Ellis, R.3
-
62
-
-
0029791026
-
Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels
-
Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol. 1996;77:1993-9.
-
(1996)
J Gen Virol
, vol.77
, pp. 1993-1999
-
-
Moog, C.1
Kuntz-Simon, G.2
Caussin-Schwemling, C.3
Obert, G.4
-
63
-
-
33750485028
-
Valproic acid does not affect markers of human immunodeficiency virus disease progression
-
Ances B, Letendre S, Buzzell M, et al. Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol. 2006;12:403-6.
-
(2006)
J Neurovirol
, vol.12
, pp. 403-406
-
-
Ances, B.1
Letendre, S.2
Buzzell, M.3
-
64
-
-
0038037673
-
Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients
-
Romanelli F, Pomeroy C. Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Curr Pharm Des. 2003;9:1433-9.
-
(2003)
Curr Pharm des
, vol.9
, pp. 1433-1439
-
-
Romanelli, F.1
Pomeroy, C.2
-
65
-
-
57649134379
-
Antiepileptic drug interactions
-
Díaz R, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist. 2008;14(Suppl 1):S55-65.
-
(2008)
Neurologist
, vol.14
, Issue.SUPPL. 1
-
-
Díaz, R.1
Sancho, J.2
Serratosa, J.3
-
67
-
-
0034127381
-
Carbamazepine-indinavir interaction causes antiretroviral therapy failure
-
Hugen P, Burger D, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother. 2000;34:465-70.
-
(2000)
Ann Pharmacother
, vol.34
, pp. 465-470
-
-
Hugen, P.1
Burger, D.2
Brinkman, K.3
-
68
-
-
0037545484
-
Lamotrigine for HIV-associated painful sensory neuropathies: A placebo controlled trial
-
Simpson D, McArthur J, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo controlled trial. Neurology. 2003;60:1508-14.
-
(2003)
Neurology
, vol.60
, pp. 1508-1514
-
-
Simpson, D.1
McArthur, J.2
Olney, R.3
-
69
-
-
33746752084
-
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in health subjects
-
van der Lee M, Dawood L, ter Hofstede HJ, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in health subjects. Clin Pharmacol Ther. 2006;80:159-68.
-
(2006)
Clin Pharmacol Ther
, vol.80
, pp. 159-168
-
-
Van Der Lee, M.1
Dawood, L.2
Ter Hofstede, H.J.3
-
70
-
-
8744261620
-
German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies
-
Hahn K, Arendt G, Braun J, et al. German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004;251:1260-6.
-
(2004)
J Neurol
, vol.251
, pp. 1260-1266
-
-
Hahn, K.1
Arendt, G.2
Braun, J.3
-
71
-
-
36949037520
-
Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy
-
Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27-47.
-
(2008)
CNS Drugs
, vol.22
, pp. 27-47
-
-
Landmark, C.1
-
72
-
-
76349097543
-
Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial
-
Simpson D, Schifitto G, Clifford D, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74:413-20.
-
(2010)
Neurology
, vol.74
, pp. 413-420
-
-
Simpson, D.1
Schifitto, G.2
Clifford, D.3
-
73
-
-
0028029552
-
Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: A clinico-pathological case report
-
Factor S, Podskalny G, Barron K. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J Neurol Sci. 1994;127:114-20.
-
(1994)
J Neurol Sci
, vol.127
, pp. 114-120
-
-
Factor, S.1
Podskalny, G.2
Barron, K.3
-
74
-
-
0026093555
-
Extrapyramidal symptoms due to dopamine blocking agents in patients with AIDS encephalopathy
-
Hriso E, Kuhn T, Masdeu J, Grundham M. Extrapyramidal symptoms due to dopamine blocking agents in patients with AIDS encephalopathy. Am J Psychiatry. 1991;148:1558-61.
-
(1991)
Am J Psychiatry
, vol.148
, pp. 1558-1561
-
-
Hriso, E.1
Kuhn, T.2
Masdeu, J.3
Grundham, M.4
-
75
-
-
0032532747
-
Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient
-
Meyer J, Marsh J, Simpson G. Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient. Biol Psychiatry. 1998;44:791-4.
-
(1998)
Biol Psychiatry
, vol.44
, pp. 791-794
-
-
Meyer, J.1
Marsh, J.2
Simpson, G.3
-
76
-
-
4644354707
-
Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care
-
Nasrallah H, Newcomer J. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(Suppl 1):S7.
-
(2004)
J Clin Psychopharmacol
, vol.24
, Issue.SUPPL. 1
-
-
Nasrallah, H.1
Newcomer, J.2
-
77
-
-
0032945422
-
Pilot study with clozapine in patients with HIV associated psychosis and drug-induced Parkinsonism
-
Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV associated psychosis and drug-induced Parkinsonism. Mov Disord. 1999;14:128-31.
-
(1999)
Mov Disord
, vol.14
, pp. 128-131
-
-
Lera, G.1
Zirulnik, J.2
-
78
-
-
0036325312
-
Influence of ritonavir on olanzapine pharmacokinetics in health volunteers
-
Penzak S, Hon Y, Lawhorn W, et al. Influence of ritonavir on olanzapine pharmacokinetics in health volunteers. J Clin Psychopharmacol. 2002;22:366-70.
-
(2002)
J Clin Psychopharmacol
, vol.22
, pp. 366-370
-
-
Penzak, S.1
Hon, Y.2
Lawhorn, W.3
-
79
-
-
0030919357
-
Treatment of HIV related psychotic disorders with risperidone: A series of 21 cases
-
Singh A, Golledge H, Catalan J. Treatment of HIV related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res. 1997;42:489-93.
-
(1997)
J Psychosom Res
, vol.42
, pp. 489-493
-
-
Singh, A.1
Golledge, H.2
Catalan, J.3
-
80
-
-
70350516833
-
Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients
-
Pollack T, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009;29:1386-91.
-
(2009)
Pharmacotherapy
, vol.29
, pp. 1386-1391
-
-
Pollack, T.1
McCoy, C.2
Stead, W.3
-
81
-
-
0036785221
-
Interactions between recreational drugs and antiretroviral agents
-
Antoniou T, Tseng A. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;36:1598-613.
-
(2002)
Ann Pharmacother
, vol.36
, pp. 1598-1613
-
-
Antoniou, T.1
Tseng, A.2
-
82
-
-
33646776797
-
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice
-
Bruce R, Altice F, Gourevitch M, Friedland G. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;4:563-72.
-
(2006)
J Acquir Immune Defic Syndr
, vol.4
, pp. 563-572
-
-
Bruce, R.1
Altice, F.2
Gourevitch, M.3
Friedland, G.4
-
83
-
-
18744399306
-
Antiretrovirals. Part III: Antiretrovirals and drugs of abuse
-
Wynn G, Cozza K, Zapor M, et al. Antiretrovirals. Part III: antiretrovirals and drugs of abuse. Psychosomatics. 2005;46:79-87.
-
(2005)
Psychosomatics
, vol.46
, pp. 79-87
-
-
Wynn, G.1
Cozza, K.2
Zapor, M.3
-
84
-
-
0038193696
-
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
-
Wang J, DeVane C. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003;31:742-7.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 742-747
-
-
Wang, J.1
DeVane, C.2
-
85
-
-
33845388480
-
Pharmacokinetic interactions between buprenorphine and antiretroviral medications
-
Bruce R, McCance-Katz E, Karasch E, Moody D, Morse G. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006;43:S216-23.
-
(2006)
Clin Infect Dis
, vol.43
-
-
Bruce, R.1
McCance-Katz, E.2
Karasch, E.3
Moody, D.4
Morse, G.5
-
86
-
-
33845419520
-
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine
-
McCance-Katz E, Moody D, Morse G, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006;43(Suppl 4):S224-34.
-
(2006)
Clin Infect Dis
, vol.43
, Issue.SUPPL. 4
-
-
McCance-Katz, E.1
Moody, D.2
Morse, G.3
-
87
-
-
33845416796
-
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ ritonavir, and ritonavir
-
McCance-Katz E, Moody D, Smith P, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ ritonavir, and ritonavir. Clin Infect Dis. 2006;43(Suppl 4):S235-46.
-
(2006)
Clin Infect Dis
, vol.43
, Issue.SUPPL. 4
-
-
McCance-Katz, E.1
Moody, D.2
Smith, P.3
-
88
-
-
0037268147
-
Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users
-
Clarke S, Delamere S, McCullough L, et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users. HIV Med. 2003;4:33-7.
-
(2003)
HIV Med
, vol.4
, pp. 33-37
-
-
Clarke, S.1
Delamere, S.2
McCullough, L.3
-
89
-
-
2342584779
-
Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and nelfinavir
-
McCance-Katz E, Rainey P, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict. 2004;13:163-80.
-
(2004)
Am J Addict
, vol.13
, pp. 163-180
-
-
McCance-Katz, E.1
Rainey, P.2
Smith, P.3
-
90
-
-
7244226310
-
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients
-
Stocker H, Kruse G, Kreckel P, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004; 48:4148-53.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 4148-4153
-
-
Stocker, H.1
Kruse, G.2
Kreckel, P.3
|